FDA Issues Complete Response Letter for Capricor’s Deramiocel BLA
The FDA issued a complete response letter to Capricor for its Deramiocel biologics license application for Duchenne muscular dystrophy.
Story updates
11:44:28 PM UTC
SquawkNews
UPDATE 1-US FDA declines to approve Capricor's cell therapy for Duchenne muscular dystrophy; shares